Tasquinimod: A novel angiogenesis inhibitor-development in prostate cancer

Saby George; Roberto Pili

doi:10.1007/s11912-013-0295-7

Tasquinimod: A novel angiogenesis inhibitor-development in prostate cancer

Saby George, Roberto Pili

Research output: Contribution to journal › Article › peer-review

5 Scopus citations

Abstract

Castration resistant prostate cancer (CRPC) treatment has been revolutionized over the past few years by the approval of novel therapies including cabazitaxel, sipuleucel-T, abiraterone and enzalutamide. Though androgen deprivation and chemotherapy remain the main therapeutic approaches for this disease, a series of targeted agents is also in development for the treatment of CRPC. Tasquinimod is a quinolone-3-carboxamide with antiangiogenic and antitumor activity in preclinical models of prostate cancer. A recent Phase II trial with this agent has demonstrated a significant clinical activity in asymptomatic or minimally symptomatic, chemotherapy-naïve, CRPC patients. A confirmatory Phase III trial of tasquinimod in prostate cancer is underway. Because of its antiangiogenic and immunomodulatory properties tasquinimod represents a novel targeted therapy with a unique mechanism of action.

Original language	English (US)
Pages (from-to)	65-68
Number of pages	4
Journal	Current Oncology Reports
Volume	15
Issue number	2
DOIs	https://doi.org/10.1007/s11912-013-0295-7
State	Published - Apr 2013
Externally published	Yes

Keywords

Adenocarcinoma of prostate
Angiogenesis inhibitor
Castration resistant prostate cancer (CRPC)
Targeted therapy

ASJC Scopus subject areas

Oncology

Access to Document

10.1007/s11912-013-0295-7

Cite this

@article{80ec0af4162440c298ad60691a4026c6,

title = "Tasquinimod: A novel angiogenesis inhibitor-development in prostate cancer",

abstract = "Castration resistant prostate cancer (CRPC) treatment has been revolutionized over the past few years by the approval of novel therapies including cabazitaxel, sipuleucel-T, abiraterone and enzalutamide. Though androgen deprivation and chemotherapy remain the main therapeutic approaches for this disease, a series of targeted agents is also in development for the treatment of CRPC. Tasquinimod is a quinolone-3-carboxamide with antiangiogenic and antitumor activity in preclinical models of prostate cancer. A recent Phase II trial with this agent has demonstrated a significant clinical activity in asymptomatic or minimally symptomatic, chemotherapy-na{\"i}ve, CRPC patients. A confirmatory Phase III trial of tasquinimod in prostate cancer is underway. Because of its antiangiogenic and immunomodulatory properties tasquinimod represents a novel targeted therapy with a unique mechanism of action.",

keywords = "Adenocarcinoma of prostate, Angiogenesis inhibitor, Castration resistant prostate cancer (CRPC), Targeted therapy",

author = "Saby George and Roberto Pili",

year = "2013",

month = apr,

doi = "10.1007/s11912-013-0295-7",

language = "English (US)",

volume = "15",

pages = "65--68",

journal = "Current Oncology Reports",

issn = "1523-3790",

publisher = "Current Science, Inc.",

number = "2",

}

TY - JOUR

T1 - Tasquinimod

T2 - A novel angiogenesis inhibitor-development in prostate cancer

AU - George, Saby

AU - Pili, Roberto

PY - 2013/4

Y1 - 2013/4

N2 - Castration resistant prostate cancer (CRPC) treatment has been revolutionized over the past few years by the approval of novel therapies including cabazitaxel, sipuleucel-T, abiraterone and enzalutamide. Though androgen deprivation and chemotherapy remain the main therapeutic approaches for this disease, a series of targeted agents is also in development for the treatment of CRPC. Tasquinimod is a quinolone-3-carboxamide with antiangiogenic and antitumor activity in preclinical models of prostate cancer. A recent Phase II trial with this agent has demonstrated a significant clinical activity in asymptomatic or minimally symptomatic, chemotherapy-naïve, CRPC patients. A confirmatory Phase III trial of tasquinimod in prostate cancer is underway. Because of its antiangiogenic and immunomodulatory properties tasquinimod represents a novel targeted therapy with a unique mechanism of action.

AB - Castration resistant prostate cancer (CRPC) treatment has been revolutionized over the past few years by the approval of novel therapies including cabazitaxel, sipuleucel-T, abiraterone and enzalutamide. Though androgen deprivation and chemotherapy remain the main therapeutic approaches for this disease, a series of targeted agents is also in development for the treatment of CRPC. Tasquinimod is a quinolone-3-carboxamide with antiangiogenic and antitumor activity in preclinical models of prostate cancer. A recent Phase II trial with this agent has demonstrated a significant clinical activity in asymptomatic or minimally symptomatic, chemotherapy-naïve, CRPC patients. A confirmatory Phase III trial of tasquinimod in prostate cancer is underway. Because of its antiangiogenic and immunomodulatory properties tasquinimod represents a novel targeted therapy with a unique mechanism of action.

KW - Adenocarcinoma of prostate

KW - Angiogenesis inhibitor

KW - Castration resistant prostate cancer (CRPC)

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=84879600997&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879600997&partnerID=8YFLogxK

U2 - 10.1007/s11912-013-0295-7

DO - 10.1007/s11912-013-0295-7

M3 - Article

C2 - 23334511

AN - SCOPUS:84879600997

SN - 1523-3790

VL - 15

SP - 65

EP - 68

JO - Current Oncology Reports

JF - Current Oncology Reports

IS - 2

ER -

Tasquinimod: A novel angiogenesis inhibitor-development in prostate cancer

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this